Biotech Startups

Greywolf is a clinical-stage biotech developing antigen modulation therapies, including oral small molecules in Phase 1/2 trials, for people with cancers and autoimmune disorders.

4 investors

Nexoplex Bio develops immunotherapies designed to target tumors through recognition of HLA-peptide complexes using multi-specific antibodies, aimed at cancers including certain lung, gastric, esophageal, head and neck, and cervical cancers. The company works at the intersection of cancer genomics and immunotherapy.

4 investors

Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma. The company works at the intersection of cancer genomics and immunotherapy and is based at MBC Biolabs in San Carlos, California.

4 investors

GRObio (GRO Biosciences) develops protein therapeutics using non-standard amino acids (NSAAs) via its GRO platform, aiming to improve protein potency, stability, and function. Its pipeline is built on two NSAA chemistry families—DuraLogic for therapeutic stability and dosing, and ProGly for biologics addressing autoimmune disease and immunogenicity.

4 investors

Grove AI builds "Grace," an AI agent and participant relationship management (PRM) platform that automates clinical trial recruitment tasks such as prescreening, participant inquiries, and appointment scheduling. It serves clinical research sites, CROs, and pharmaceutical sponsors in the life sciences industry.

4 investors

GT Medical Technologies develops GammaTile, an implantable radiation therapy device for treating operable brain tumors. The FDA-cleared bioresorbable collagen tile is placed during tumor removal surgery to deliver targeted radiation and reduce regrowth risk while protecting healthy brain tissue.

4 investors

Hadean Ventures is a European venture capital fund manager with over EUR 230 million in assets under management, with a track record in life sciences. The firm invests across sectors and stages, focusing on science-driven innovation and healthcare.

4 investors

Haplotype Labs develops population genetics software and polygenic risk scores with improved security, accessibility, and sophistication to enhance human healthspan. The company serves researchers, healthcare providers, and consumers seeking genetic risk assessment tools.

4 investors

Harmonic Discovery applies medicinal chemistry, cheminformatics, data science and machine learning expertise to advance drug discovery. The company is supported by investors at the intersection of technology, biology and medicine.

4 investors

Hepatx develops regenerative medicine treatments delivered via infusion as an alternative to organ transplants for patients with chronic liver disease. The company focuses on repairing diseased and damaged liver tissue.

4 investors

Herophilus develops neurological drug discovery by combining human brain models, scaled biology, and machine learning to identify and develop novel drugs for complex brain diseases. It operates in the biotech and neuroscience drug development space.

4 investors

Vitra Bio is a biotechnology company developing technology aimed at transforming fertility treatment. Its work is supported by clinical and scientific advisors in reproductive medicine and cell biology.

4 investors

Huue produces bio-based indigo dye for the denim industry using bioengineered microbes that convert sugar into pigment, replacing toxic chemical and petroleum-based processes. The company's sustainable indigo is compatible with existing manufacturing and reduces toxicity, fossil fuel use, and water pollution in denim production.

4 investors

Vaccine development platform using computationally designed synthetic virus-like particles

4 investors

A pharmaceutical company that develops medicines and vaccines, with research pipelines and clinical trials aimed at new treatments. It has operated for over 130 years and serves patients and healthcare needs globally.

4 investors

Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion. The company combines validated biological targets with drug design and clinical strategies aimed at improving patient outcomes through precision medicine approaches.

4 investors

The page is a stock price information page (share price, trading volume, and market cap history) rather than a descriptive company page, so it provides no usable detail about what the company does.

4 investors

Biotechnology company developing orally available therapies for chronic inflammatory and autoimmune diseases.

4 investors

Immunocore is a biotechnology company developing T cell receptor (TCR) based immunomodulating therapies for patients with cancer, infectious diseases, and autoimmune diseases.

4 investors

ImmunoForge is a South Korean drug development company that builds a pipeline of therapeutics based on its ELP (elastin-like polypeptide) half-life extension platform and a blood-brain-barrier shuttle platform (LMT15). Its programs include candidates for chronic myelogenous leukemia (KF1601) and Duchenne muscular dystrophy cardiomyopathy (Pemziviptadil).

4 investors

Immutrin is a biotechnology company developing antibody therapies designed to remove systemic amyloid deposits and reverse amyloidosis. Its lead program targets ATTR cardiomyopathy, a progressive form of amyloidosis.

4 investors

Implexis blends pharmaceutical expertise with automation to deliver impact in the life sciences industry.

4 investors

Inari applies artificial intelligence and gene editing to accelerate plant breeding, delivering crop improvement solutions for farmers focused on soybeans, corn, and wheat across broadacre agriculture.

4 investors

Indee Labs develops a non-viral intracellular delivery system based on microfluidic vortex shedding (µVS) to deliver nucleic acids, proteins, and gene editing complexes into patient and donor T cells. The technology targets T cell immunotherapy discovery, development, and manufacturing.

4 investors